Table 4.

Secondary outcomes: cardiovascular endpoints at month 12 in RTR-PD subpopulation

ParameterBelatacept MI (n = 114)Belatacept LI (n = 97)CsA (n = 125)
Serum lipids
    non-HDL cholesterol
        mean change from baseline, mg/dl (SE)7.9 (4.2)11.3 (4.7)14.9 (4.3)
        estimated difference from CsA (97.3% CI)−6.9 (−20.3 to 6.4)−3.6 (−17.8 to 10.6)
    triglycerides
        mean change from baseline, mg/dl (SE)−26.5 (13.8)−25.6 (14.7)−9.9 (14.3)
        estimated difference from CsA (97.3% CI)−16.7 (−60.7 to 27.4)−15.7 (−61.0 to 29.6)
        blood pressure (mmHg)
    mean systolic BP (SD)139.1 (18.5)139.5 (19.3)145.3 (23.8)
    mean diastolic BP (SD)76.7 (12.5)77.0 (9.1)79.1 (10.7)
Patients receiving medications
    ≥1 antihyperlipidemic medication, n (%)54 (47.4)48 (49.5)67 (53.6)
        95% CI38.2 to 56.539.5 to 59.444.9 to 62.3
    ≥1 antihypertensive medication, n (%)98 (89.1)85 (89.5)113 (93.4)
        95% CI83.3 to 94.983.3 to 95.689.0 to 97.8
    ≥3 antihypertensive medications, n (%)45 (40.9)34 (35.8)56 (46.3)
  • CsA is the referent group in this analysis. CI, confidence interval; CsA, cyclosporine; LI, less intensive; MI, more intensive; RTR-PD, renal transplant recipients with preexisting diabetes.